Despite these promising preclinical studies, a phase 1b/2 clinical trial evaluating CSF-1R inhibition in combination with radiotherapy and temozolomide for newly diagnosed glioblastoma did not improve median PFS or overall survival compared to historical controls (NCT01790503) (96). The gene discussed is CSF1R; the disease is glioblastoma.